Du är här


Bionor Pharma ASA: Notice of results for the fourth quarter and full year ended 31 December 2015



Notice of results for the fourth quarter and full year ended 31 December 2015
(Oslo, Norway, 8 February 2016) Bionor Pharma ASA (OSE:BIONOR) will report its
financial results for the fourth quarter and full year ended 31 December 2015
on 12 February 2016 at no later than 11:30 CET.

Bionor will host a conference call for analysts and investors 12 February 2016
at 13:00 CET at which David H. Solomon, President and CEO, and Jens Krøis,
CFO, will provide an update of the business. To attend the conference, please
use theparticipant code 1059479

Norway: +47 2316 2771
Denmark: +45 32 71 16 58
United Kingdom: +44 20 3427 1905
USA: +1 646 254 3365
Sweden: +46 8 5033 6538

A presentation will be available on the company's website prior to the call. A
webcast of the conference call will be available during and after the event.
Link to webcast:http://edge.media-server.com/m/p/wrriyzu2.

Further information

Jørgen Fischer Ravn, VP Investor Relations&Communications, +45 20 30 39

About Bionor

Bionor Pharma is a Norwegian biopharmaceutical company focused on advancing
its proprietary therapeutic vaccine Vacc-4x in combination with other
medicines toward a functional HIV cure. The company believes it has first
mover potential based on clinical results to date and early adoption of now
recognized clinical strategy. In December 2015, Bionor announced that the HIV
'Shock&Kill' trial REDUC with Vacc-4x and romidepsin successfully met its
primary endpoint by reducing latent HIV reservoir and further demonstrated
control of viral load. Bionor is currently planning BIOSKILL, a
proof-of-concept Phase II trial, which may lead to a major value inflection
point and partnering opportunities. Bionor currently retains full ownership
rights to Vacc-4x, i.e., the upside potential from partnering or licensing
remains with the company. Bionor is based in Oslo, Norway, and also has
offices in Copenhagen, Denmark and New York, USA. Bionor is listed on Oslo
Børs (OSE:BIONOR). More information about Bionor is available

Q4 2015 TC notice


This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Bionor Pharma ASA via Globenewswire


Författare WKR

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.